# EDGAR Filing Document

**Accession Number:** 0000926617
**File Stem:** 0000926617-23-000016
**Filing Date:** 2023-3
**Character Count:** 5558
**Document Hash:** 94a22c7d417a84202b54a80da3c7cc0b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000926617-23-000016.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0000926617-23-000016

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230228

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230303

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aspira Women's Health Inc.
- **CENTRAL INDEX KEY:** 0000926617
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 330595156
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34810
- **FILM NUMBER:** 23705640

**BUSINESS ADDRESS:**
- **STREET 1:** 12117 BEE CAVES ROAD BUILDING THREE
- **STREET 2:** SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738
- **BUSINESS PHONE:** 512-519-0400

**MAIL ADDRESS:**
- **STREET 1:** 12117 BEE CAVES ROAD BUILDING THREE
- **STREET 2:** SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VERMILLION, INC.
- **DATE OF NAME CHANGE:** 20070824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CIPHERGEN BIOSYSTEMS INC
- **DATE OF NAME CHANGE:** 20000316

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ABIOTIC SYSTEMS
- **DATE OF NAME CHANGE:** 19950407

?xml version="1.0" encoding="utf-8"? awh-20230228x8k

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Form 8-K** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of** 

**the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): February 28, 2023**

**Aspira Women's Health Inc.** 

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34810** | **33-0595156** |
| (State or other jurisdiction<br>‎of incorporation) | (Commission<br>‎File Number) | (IRS Employer<br>‎Identification No.) |

---

---

| | |
|:---|:---|
| **12117 Bee Caves Road, Building III, Suite 100, Austin, Texas** | **78738** |
| (Address of principal executive offices) | (Zip Code) |

---

**Registrant's telephone number, including area code: (512) 519-0400** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| <u>Title of each class</u> | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
| Common Stock, par value $0.001 per share | AWH | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) <u>Appointment of Chair of the Board</u>

On February 28, 2023, the board of directors (the "Board") of Aspira Women's Health Inc. (the "Company") appointed Dr. Veronica G.H. Jordan as the Chair of the Board, effective as of March 1, 2023. In conjunction with this appointment, Dr. Robert Auerbach stepped down as the Company's Lead Independent Director, effective as of March 1, 2023.

<u>Termination of Employment and Resignation as Executive Chair of the Board</u>

In accordance with the terms of that certain Amended and Restated Employment Agreement effective as of March 1, 2022 between the Company and Valerie Palmieri (the "Palmieri Agreement"), Ms. Palmieri's term as Executive Chair of the Company concluded on March 1, 2023. In addition, pursuant to the Palmieri Agreement, Ms. Palmieri resigned as a director of the Board effective as of March 1, 2023.

## Item 9.01. Financial Statements and Exhibits
(d) *Exhibits.*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) |

---

 **‎** 

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ASPIRA WOMEN'S HEALTH INC.**

---

| | | | |
|:---|:---|:---|:---|
| Date: | March 3, 2023 | By: | /s/ Minh Merchant |
|  |  |  | Minh Merchant |
|  |  |  | Secretary and General Counsel |

---